OmniComm’s TrialMaster EDC Selected by Sorrento Therapeutics for Cancer Research

September 20, 2018

Applied Clinical Trials

Sorrento Therapeutics, Inc., a clinical stage, antibody-centric, biopharmaceutical company, has signed a new agreement with OmniComm Systems, Inc., a global provider of clinical data management technology, in which they will use OmniComm’s TrialMaster EDC technology to develop clinical studies at multiple Sorrento research sites.

Read the full release here.